The use of psychostimulants in palliative and supportive treatment of cancer patients by Kaminski, Marek & gren, Per Sj
www.advpm.eu 23
Review article
Address for correspondence: Marek Kaminski
Department of Anaesthesiology
Vejle Hospital, Kabbeltoft 25, 7100 Vejle, Denmark
tel: +45 79406200, fax: +45 79406875
e-mail: marek_kam@yahoo.dk
Advances in Palliative Medicine 2007, 6, 2331
Copyright ' 2007 Via Medica
Marek Kaminski1, Per Sjłgren2
1Department of Anaesthesiology, Vejle Hospital, Vejle, Denmark
2Multidisciplinary Pain Centre, National Hospital, Copenhagen, Denmark
The use of psychostimulants in
palliative and supportive treatment
of cancer patients
Abstract
Psychostimulants have been used in psychiatric and medically ill patients. The need to control and counter-
act the multiple distressing symptoms related to cancer and its treatment has brought this group of
medications into palliative and supportive care of cancer patients. Psychostimulants have been studied and
used in symptoms like cancer-related fatigue, cognitive dysfunction, depression and sedation. This review
discusses the pharmacology of methylphenidate, amphetamine and pemoline and other psychostimulants
like caffeine and the novel wake-promoting drug, modafinil. Studies evaluating use of these drugs in cancer
patients have been reviewed.
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Introduction
A psychostimulant is a drug, which by inducing
certain brain activities causes a sense of well being,
decreases fatigue and depression, improves cogni-
tive and intellectual function and enhances motiva-
tion. Different drugs belonging to various pharma-
cological groups are defined as psychostimulants.
Among those are naturally occurring substances like
cocaine and caffeine and synthetic drugs like am-
phetamine or methylphenidate. Naturally occurring
substances with psychostimulating properties has
been consumed through centuries in different cul-
tures. For example cocaine obtained from coca plant
were used for its stimulating properties by ancient
peoples of Peru and other pre-Columbian Andean
societies. It was also one of the original ingredients
of Coca-Cola until its highly addictive properties were
recognized, and it was replaced by caffeine in 1903.
Currently, cocaine is illicit all over the world and its
legal use is limited to local analgesia in ophtalmic
surgery. Caffeine, the most commonly used psycho-
stimulant is consumed worldwide in coffee, tea and
variety of soft drinks, and is also a component of
many popular medications as well. Amphetamine,
which was synthetized in 1887, was used by military
forces in twentieth century to improve alertness dur-
ing sustained war operations. In sixties and seven-
ties amphetamine abuse became epidemic and re-
strictions of its availability in majority of European
countries were accomplished. Novel drugs  like
modafinil  with less abuse potential has been de-
veloped recently. Modafinil acts more selectively on
the sleep-wake cycle instead of promoting general-
ized activation of CNS. Commonly accepted indica-
tions for psychostimulants include attention deficit/
/hyperactivity syndrome (ADHD) and narcolepsy.
Moreover, psychostimulants have been used to treat
Advances in Palliative Medicine 2007, vol. 6, no. 1
www.advpm.eu24
a variety of symptoms accompanying different dis-
eases. They have been used i.e. for the treatment of
fatigue in patients with multiple sclerosis or HIV
disease or as a adjuvant medication for major de-
pression.
Cancer diseases and anticancer treatments are
accompanied by various severe and prevalent symp-
toms, which diminish quality of life of the patients,
and are usually difficult to combat. These include
fatigue, sedation and cognitive dysfunction.
Several authors have investigated psychostimu-
lants in cancer patients. The aim of this article is to
review the available literature on psychostimulants in
palliative and supportive treatment of cancer patients.
Pharmacology of psychostimulants
and their use in cancer patients
Methylphenidate
Pharmacology
Methylphenidate (MP) is a piperidine derivative
and like amphetamine and catecholamines it has a
phenylethyloamine structure [13]. Because the MP
molecule has two chiral centers it exists as four enan-
tiomers: d- and l-threo-metylphenidate and d- and
l-erythro-methylphenidate [4]. Most of clinically used
preparations of MP contains a mixture of d- and l-
isomers of threo- form [1, 5]. An exception is Fo-
calinTM (Novartis Pharmaceuticals) which contains
primarily a d-isomer [1]. MP is well absorbed from
the gastrointestinal tract and achieves peak blood
levels within 1 to 2 hours [6]. Absorbed drug under-
goes extensive first-pass metabolism and has an elim-
ination half-life of 2 to 7 hours [6]. Its major metab-
olite, ritalinic acid, is mainly excreted in the urine [6].
Clinical effect of MP has duration of 3 to 5 hours.
Several commercially available products include also
sustained-release preparations with duration of ac-
tion up to 12 hours [1,6].
The exact mechanism of action of MP is not fully
elucidated. Evidence from animal and human stud-
ies indicates that MP increases extra-cellular dopam-
ine levels in the brain by blocking dopamine re-
uptake and by facilitation of dopamine release into
the synaptic cleft [1, 7]. It has also been shown that
MP blocks dopamine re-uptake by binding to the
dopamine transporters in the presynaptic cell mem-
brane [8, 9]. This differs from the main mechanism
of action of amphetamine, which releases newly
synthesized cytosolic dopamine from the nerve ter-
minal [10]. The dopamine transporters is thought to
be a critical regulator of dopamine homeostasis [8,
11]. At oral therapeutic doses (0.30.6 mg/kg), me-
thylphenidate is estimated to occupy more than half
of brain dopamine transporters. Studies using sin-
gle-photon emission tomography have shown that
the striatum is the area of highest methylphenidate
uptake in the human brain [6, 12, 13]. MP blocks
also re-uptake of norepinephrine and binds weakly
to the serotonine transporters, but the effect on
these two neurotransmitters, particularly serotonine,
appears to be weaker compared with the effect on
dopamine [14]. Recent research has shown another
possible mechanism of action: methylphenidate can
increase prefrontal cortex excitability by activation
of alpha-2-adrenoreceptors in inhibitory interneu-
rons [15].
MP is a relatively safe drug and few side effects
have been demonstrated in clinical trial settings. The
most common side effects include insomnia, nervous-
ness, tachycardia, hypertension and anorexia [1, 2].
In adults anorexia is not observed as side effect [16].
An overdose of MP is associated with symptoms
of CNS overstimulation and sympathomimetic effects,
and can usually be treated symptomatically [1].
MP potentiates effects of tricyclic antidepressants,
MAO inhibitors and coumarin anticoagulants. Ef-
fects of central adrenergic blockers are antagonised
by MP [2].
MP has abuse potential as it can induce euphoria.
However, abuse of oral MP seems not to be an im-
portant problem in medically ill population [2]. Used
intravenously or intranasally MP has a cocaine-like
effect with clinically important abuse potential [17].
The majority of clinical experience with MP comes
from its use in patients with attention-deficit/hyper-
activity disorder (ADHD) [18, 19].
The Food and Drug Administration (FDA, United
States regulative body for drugs) has approved MP
for the treatment of ADHD and narcolepsy. The same
diseases are officially approved indications for the
use of MP in Denmark, and in Poland MP is only
approved for the treatment of ADHD.
Use in patients with cancer
MP has been investigated as a remedy to relieve
several symptoms associated with cancer and its
treatment. These include very frequent and serious
symptoms and side effects as depression, opioid-
induced sedation, cognitive dysfunction and fatigue.
The potential of MP as an adjuvant drug in cancer
patients has been evaluated in several studies.
Opioid-induced sedation. Many patients with
advanced cancer require high doses of opioids to
control their pain. Sedation is a well-described and
frequent side effect of opioid drugs that may be
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present for long periods of time and may be associ-
ated with poor quality of life. Moreover during opi-
oid treatment sedation can be a limiting factor for
achieving desirable analgesia. The prevalence of opi-
oid induced sedation was 33% in a mixed popula-
tion of hospitalised cancer patients [20]. MP effect
can counteract opioid-induced sedation.
Open-label studies. In a non-randomised study
involving 15 patients with incident cancer pain
10 mg MP was administered at 08.00 h a.m. and 5 mg
at 12.00 h a.m. in order to counteract opioid-in-
duced sedation [21]. This allowed for higher doses
of opioids, which, in turn resulted in better pain
control and less drowsiness. In another non-ran-
domised study involving 50 patients with advanced
cancer and opioid-induced sedation MP was started
at a dose of 15 mg/day [22]. The majority (91%) of
48 evaluated patients reported improvement in se-
dation after 48 hours of treatment and continued
on MP for mean 39 – 20 days. However, due to
development of tolerance, the doses of MP were
increased the following month. The mean maximal
daily dose of MP in this study reached 42 – 6 mg.
Randomised controlled trials. The effects of MP
in opioid-induced sedation were also investigated in
three randomised, double-blind, placebo controlled,
cross-over studies.
In the first study, 32 patients with advanced can-
cer receiving opioids were randomised to receive
MP (10 mg in the morning and 5 mg at noon) or
placebo. Patients receiving MP showed improvement
in pain, activity and sedation scores [23]. The sec-
ond study evaluated effects of MP (20 mg daily)
compared to placebo on sedation and cognitive func-
tion in twenty patients receiving a continuous infu-
sion of opioids for cancer pain. Cognitive functions
were assessed by means of several tests like finger
tapping speed, arithmetic tests, and memory for
digits and visual memory. MP resulted in significant
improvement in drowsiness, confusion and cogni-
tive functions [24].
The third study involved 43 cancer patients re-
ceiving stable doses of oral opioids . Patients were
randomised to receive 5 days of MP followed by
5 days placebo, or vice versa. The dose of MP used in
this study was 10 mg in the morning and 5 mg at
noon (5 mg in the morning and 5 mg at noon for
patients aged 70 years or over). Thirty-four patients
completed all 10 days of double-blind assessment.
Data from this study did not demonstrate statisti-
cally significant benefit of methylphenidate, but
suggested that this drug could mildly decrease opi-
oid-induced drowsiness and improve night-time
sleep [25].
Depression. Depression is frequently seen in pa-
tients with advanced cancer [26]. The prevalence of
major depression in palliative care cancer patients
have recently been found to be 47% [27]. Treatment
of these patients with antidepressants is hampered
by the slow onset of effects seen in relation to the
short life expectancy. Psychostimulants may have
antidepressant effects and may be advantageous
due to the rapid onset of action.
Open-label studies. MP has been evaluated as
a remedy for depression in a number of non-ran-
domised studies. In a case series of five organically
impaired and depressed patients with head and neck
cancer, rapid remission of depressive symptoms and
improvement in cognition was reported after initi-
ating MP therapy [28]. In another study 59 hospital
charts of oncology patients, who were treated for
depression with either dextro-amphetamine or MP,
were reviewed retrospectively. Eighty-three percent
of the patients showed at least some improvement,
while 73% had marked or moderate improvement
of depressive symptoms following psychostimulant
treatment. There was no significant difference in
efficacy between the two psychostimulants [29].
An open-label study evaluated efficacy of MP
(520 mg daily) in 26 depressed hospice patients
with end-stage cancer. In 46% a moderate and in
7% a pronounced improvement of depression was
described. The author concluded, that higher doses
of psychostimulants may be indicated in terminal
phase of cancer [30].
In another case series MP (1020 mg daily) was
used to treat depression in 10 patients with ad-
vanced cancer. Rapid improvement in depressive
symptoms was noted in all patients [31].
In more recent, open-label, prospective study MP
was used to treat depression in 41 patients with
advanced cancer. Out of 30 patients, who complet-
ed the study, 21 responded to 10 mg/day and
9 responded to 20 mg/day. Improvement occurred
within three days [32].
Cognitive dysfunction. Cognitive dysfunction is
prevalent and serious in patients with advanced can-
cer, particularly, in patients with brain tumours. In
palliative care using Mini Mental State Examination
(MMSE) a study by Pereira et al. comprising 348 inpa-
tients showed a prevalence of cognitive dysfunction
of 44% on admission, whereas 68% had abnormal
MMSE scores prior to death [33]. Strömgren et al.
investigated 267 patients referred to three palliative
care functions: Inpatient, outpatient and palliative
home care. The overall prevalence of cognitive dys-
function on admission showed that 24% had abnor-
mal MMSE scores [27].
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Open-label studies. In an open-label, prospec-
tive study involving 30 patients with malignant glio-
mas, improvement in cognitive domains like atten-
tion, memory, graphomotor speed or verbal fluency
was observed in 50 percent of patients receiving MP
(1030 mg/day) despite progressing brain lesions
documented by MRI [34].
In another open-label, prospective study includ-
ing 14 patients with advanced cancer and hypoactive
delirium, cognitive function measured by MMSE im-
proved after treatment with MP in all patients [35].
Randomised controlled trials. MPs capability of
improving cognition has been evaluated in three
randomised, placebo-controlled studies.
In an older study, discussed previously in the
context of opioid-induced sedation, MP (10 mg in
the morning) also improved cognitive function (as-
sessed by finger tapping speed and arithmetic and
memory tests) in most patients receiving opioid in-
fusions [24].
Another randomised, double-blind, placebo-con-
trolled study evaluated the cognitive effects of MP
(0.6 mg/kg) in 32 long-term survivors of childhood
acute lymphoblastic leukaemia or malignant brain
tumours. Using Conners Continuous Performance
Test patients receiving MP showed significant im-
provement in sustained attention and overall index
reflecting learning capabilities. However, there was
not significant improvement in reaction times or
verbal memory [36].
The largest study involved 83 children with long-
term survival of acute lymphoblastic leukaemia or
brain tumors [37]. The children were randomised to
receive MP (0.3 mg/kg or 0.6 mg/kg) or placebo. Use
of MP resulted in improved cognitive function and
social functioning. The children were evaluated by
parents and teachers using Conners Rating Scales
and Social Skills Rating System. There was no signif-
icant advantage of higher dose (0.6mg/kg) of MP.
Cancer-related fatigue. Fatigue is among the
most frequent and among the most distressing symp-
toms experienced by cancer patients. In palliative
care the prevalence of fatigue among cancer pa-
tients is > 90% in most populations [27].
Open-label studies. The effectiveness of MP in
this symptom has been assessed in a number of
non-randomised studies in cancer patients. In
a small, prospective, open-label study MP relieved
fatigue in nine out of eleven patients with advanced
cancer. In most of the patients 10 mg methylpheni-
date daily in two divided doses was effective [38]. In
a study involving 31 cancer patients, the patients
could use 5 mg of MP as needed every 2 hours for
fatigue. Patients were allowed to take a maximum
of four tablets per day. Fatigue was measured using
0 to 10 point scale. Significant improvement from
7.2 – 1.6 score to 3.0 – 1.9 score was noticed after
seven days of treatment with MP. Most patients
preferred to take three or four doses daily [39].
In another open-label study MP was used for
treatment of fatigue in 37 patients with history of
breast cancer treated with surgery and/or chemo-
therapy and/or radiotherapy. The patients included
were disease-free for at least 6 months from the last
treatment sequence. Fatigue level was assessed us-
ing Brief Fatigue Inventory (BFI). Treatment with MP
(1020 mg/daily) resulted in improvement of fatigue
measured as a decrease in BFI scores greater than
two points in 54% of the patients [40].
Randomised controlled trials. Two randomised,
double-blind, placebo-controlled studies assessed
effectiveness of MP for cancer-related fatigue.
A study was a follow up from a pilot study [39],
in which Bruera et al. assessed patient-controlled
MP (1020 mg/daily) versus placebo in 112 cancer
patients. In contrast to the results of the pilot study,
MP was not found to be more effective than place-
bo in relieving cancer-related fatigue [39, 41]. In
another study d-isomer of MP was compared to
placebo in 152 post-chemotherapy cancer patients.
The average dose of d-MP in the study was 27.7 mg,
which is comparable to a dose of approximately
55 mg of racemic mixture. Significant relief of fa-
tigue and improved memory was observed in d-MP
group compared with placebo [42].
Amphetamine and dextroamphetamine
Pharmacology
Amphetamine is a racemic mixture of levo- and
dextrorotatory isomers. Its molecule shares a phenylo-
ethyloamine structure with catecholamines and MP
[2, 3]. The dextrorotatory form (dextroamphetamine)
is three to four times more potent than the l-isomer.
Due to its high lipophilicity, amphetamine is rapidly
and completely absorbed from the gastrointestinal tract
and easily crosses blood-brain barrier. Peak plasma
levels are achieved in 3 to 4 hours after oral adminis-
tration. Amphetamine is partially metabolised in the
liver, but a considerable fraction may be excreted in
the urine unchanged. No active metabolites are pro-
duced. The elimination half-life is approximately 12 to
20 hours and is dependent on urinary pH. Acidifica-
tion of the urine promotes the clearance of amphet-
amine. Pharmacodynamic responsivity to amphetamine
is variable and there is no good correlation between
plasma levels and clinical response. The exact mecha-
nism of action of amphetamine is unknown [3, 10].
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In animals, it facilitates catecholamine release from
neurons, reduces their reuptake and inhibits mono-
amino oxidase activity. The central psychostimulant ac-
tions are primarily dependent on interaction with
dopaminergic fibers in ventral tegmentum, mesolimbic
system and particularly in the nucleus accumbens. An-
orexic and locomotor effects depend to greater extent
on central release of norepinephrine. In addition am-
phetamine exerts mild peripheral a- and b-sympatho-
mimetic effect leading to elevation of heart rate and
blood pressure. Amphetamine like other structure-re-
lated psychostimulants is capable of producing a range
of central nervous system, cardiovascular and gas-
trointestinal side effects. Insomnia, agitation, palpita-
tions and dry mouths are among the most common.
In most cases these side effects are transient and di-
minish with the development of tolerance. Cardiac
arrhythmias, hypertension and delirium are relative,
but not absolute contraindications to a low dose am-
phetamine trial. The tolerance and abuse potential of
amphetamine seems to be related to several factors
like treatment indications, patient selection and su-
pervision of administration. Clinical experience with
cancer patients and other medically ill patients sug-
gest little if any tendency towards abuse. In contrast
uncontrolled use for fatigue and//or as a mood en-
hancer tolerance, drug abuse and chronic toxicity will
develop rapidly and frequently. Several studies con-
firm effectiveness of dextroamphetamine for depres-
sion secondary to medical illness [4346]. It has been
also found helpful in counteracting sedation resulting
from opioids in postoperative patients [47]. Few stud-
ies have assessed the usefulness of amphetamine in
cancer patients. In Denmark and Poland amphetamine
is not available legally. In the USA amphetamine is
available for treatment of ADHD, narcolepsy and re-
fractory obesity.
Use in patients with cancer
Only a few older publications can be found describ-
ing the use of amphetamines in cancer patients. In a
clinical note Yee and Berde presented experience with 4
terminally ill cancer patients, who received dextroam-
phetamine as adjuvant to opioid analgesics [48]. Using
5 or 7.5 mg dextroamphetamine daily the authors
achieved decreased somnolence and improved interac-
tion in 3 patients. In a formerly cited retrospective study
[29] in which hospital charts of oncology patients were
reviewed, 44 cancer patients received dextroamphet-
amine for depression. The daily dose of dextroamphet-
amine ranged from 2.5 to 20 mg. Seventy percent of
treated patients demonstrated marked or moderate
improvement of depressive symptoms. Mood improved
quickly, usually within the first two days of treatment.
Pemoline
Pharmacology
Pemoline is oxazolidinone derivative that is struc-
turally dissimilar to methylphenidate and amphet-
amine. The mechanism and site of action is not
known. Animal studies suggest blockage of presyn-
aptic neuron dopamine reuptake. Pemoline is readi-
ly absorbed from the gastrointestinal tract. It is par-
tially metabolised in the liver and is excreted in the
urine as both unchanged drug and metabolites [3].
In spite of short elimination half-life (t‰ = 9 to 14
hours), the onset to peak clinical effectiveness may
be a matter of days to weeks [2].
The side effect profile of pemoline is similar to
that of MP and amphetamine. From 1971 to 1985
there have been reported approximately hundred
cases of pemoline-associated hepatic toxicity [2, 49].
In the USA pemoline has been used to treat ADHD
and narcolepsy [2]. It has also been tested and dem-
onstrated to be efficacious against fatigue in pa-
tients with multiple sclerosis and HIV disease [50,
51]. There are no available studies of pemoline in
cancer patients. In 2005 FDA withdrew approval for
pemoline due to public pressure and in the same
year Abbot Laboratories discontinued the produc-
tion of pemoline.
Caffeine
Pharmacology
Caffeine is a mild CNS stimulant consumed ev-
ery day by millions of people all over the world,
mainly in coffee, tea and a variety of soft drinks.
Chemically caffeine is a methylxantine and is struc-
turally unrelated to other psychostimulants [3]. Af-
ter oral ingestion caffeine is rapidly and almost
completely absorbed from gastrointestinal tract and
easily passes through blood-brain barrier [52]. Peak
plasma concentration is reached in 3060 min af-
ter oral intake and elimination half-life is approxi-
mately 36 hours [3, 52]. Caffeine is almost com-
pletely metabolised in the liver [3]. Its mechanisms
of action are not fully understood. The presumed
mechanism of action of caffeine is an antagonism
of adenosine receptors, but an interaction with
dopamine systems within the CNS has also been
postulated [52]. Nausea, vomiting, diarrhoea, gas-
trointestinal bleeding, insomnia, headache, rest-
lessness, tremor and palpitations are possible side
effects of caffeine [3]. Prolonged high intake may
lead to tolerance and withdrawal symptoms after
abrupt discontinuation, but addiction is extremely
rare [3, 52].
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Use in patients with cancer
Only one study could be found assessing the use
of caffeine in cancer patients [53]. In a double-blind,
placebo-controlled, crossover study Mercadante et
al. assessed effects of caffeine infusion on cognitive
function in cancer patients receiving morphine.
Twelve patients participated in the study, and their
psychomotor performance was assessed using fin-
ger tapping test, arithmetic tests, memory for digits
and visual memory. Only finger tapping speed im-
proved significantly compared with placebo.
Modafinil
Pharmacology
Modafinil (2-[(diphenylmethyl) sulphinyl]acetamide)
is a novel, vigilance and wakefulness promoting CNS
stimulant. It is chemically unrelated to other psy-
chostimulants [54]. Following oral administration,
modafinil is rapidly and completely absorbed from
gastrointestinal tract, and achieves peak plasma lev-
el in two to four hours [55]. It is extensively metabo-
lised in the liver. The main metabolite is modafinil
acid, which is pharmacologically inactive. Less then
10% of a modafinil dose is excreted in urine un-
changed. The elimination half-life after a single oral
dose is between 10 and 13 hours. With multiple
daily dosing steady-state plasma levels are reached
after three days. Modafinil is moderately bound to
plasma proteins, therefore drug interactions origi-
nating from competitive protein binding are unlike-
ly [45, 56]. Important interactions of modafinil are
connected to activation or inhibition of CYP450 en-
zymes in the liver. CYP3A4 is induced by Modafinil
at doses > 400 mg/d. This may reduce serum con-
centration of co-administered drugs (i.e. carbam-
azepine, phenobarbital, ketoconazole, cyclosporine)
that are dependent on this enzyme for their metab-
olism. Two enzymes from CYP450 family (CYP2C19,
CYP2C9) have been identified as being inhibited by
modafinil. This may be of clinical importance, since
these enzymes are involved metabolism of tricyclic
antidepressants, warfarin, diazepam and phenytoin
[54, 56].
Although various neurotransmitter systems
have been proposed to be involved in the actions
of modafinil, little is still known about the molec-
ular mechanisms by which modafinil increases
wakefulness. It is likely that modafinil selectively
enhances catecholaminergic signalling in the CNS
like amphetamine and methylphenidate, but its
site of action is different. Modafinil acts primarily
in the anterior hypothalamus, an area of brain
involved in the regulation of normal wakefulness,
whereas amphetamine and methylphenidate gen-
erally act throughout the striatum and cortex [56
59]. Therefore modafinil interacts with sleep-wake
cycle, rather than inducing generalized excitation,
such as that seen with seen with other psycho-
stimulants. The fact that modafinil acts more lo-
cally within the CNS seems to be responsible, at
least in part, for its relatively low incidence of side
effects and low abuse potential [56]. Contra-indi-
cations comprise patients with left ventricular hy-
pertrophy, mitral valve prolapse or history of psy-
chosis. Modafinil is registered in many countries
including Denmark for the treatment of narcolep-
sy. It has been found effective for excessive sleep-
iness associated with obstructive apnoea/hypop-
noea syndrome [60] and against fatigue accom-
panying a variety of diseases including multiple
sclerosis and fibromyalgia [6163]. Modafinil has
also been investigated for the treatment of ADHD
[64], and as a main or adjunctive medication in
certain forms of depression [6567]. Usefulness
of modafinil against opioid-induced sedation has
been tested in patients with chronic non-malig-
nant pain [68]. Modafinil may be found useful in
the treatment of symptoms associated with can-
cer and its treatment. The number of studies ad-
dressing this problem is still very limited.
Use in patients with cancer
Open label studies. Modafinil has been tested
for persistent fatigue in patients who completed
breast cancer treatment. [69]. In an open-label study
51 patients received 200 mg modafinil (Provigilfi)
in the morning. Fatigue severity level was measured
using 010 scale, where 0 = not present and 10 =
as bad as you can imagine. The mean fatigue
severity level for the 51 participating patients was
reduced statistically significant. Furthermore major-
ity of patients reported improvement in general ac-
tivity, mood and normal work ability. Patient report-
ed global effectiveness of modafinil was mean 5.0
during this study (1 = no benefit and 7 = great
improvement). The study has been followed by a
randomised controlled study, which has not been
published yet.
Randomised studies. The only currently avail-
able randomised study assessing effects of modafi-
nil regarding cognition and fatigue was presented
in 2006 at the Annual ASCO Meeting [70]. The study
involved thirty patients with brain tumours treated
with neurosurgical resection, radiotherapy, and/or
chemotherapy. Cognitive dysfunction and depres-
sion were assessed using Trail Making (TM) A and B,
Symbol Digit Modalities (SDM), Verbal Fluency (VF),
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and Hamilton Depression Scale (HAM-D). Fatigue
was measured with Fatigue Severity Scale (FSS), Vi-
suals Analogue Fatigue Scale (VAFS), and Modified
Fatigue Impact Scale (MFIS). Patients were ran-
domised in the double-blind, dose-controlled de-
sign to receive 200 or 400mg modafinil daily for 3
weeks. After 1 week washout the study was contin-
ued for 8 weeks in open-label fashion. Statistically
significant improvement in all measured parame-
ters was observed with greatest improvement 8
weeks after baseline.
Discussion
Cancer patients experience multiple distress-
ing symptoms. Pain has long been recognized as a
common burden for patients with cancer. Tremen-
dous efforts have focussed on understanding the
mechanisms of pain and developing effective drug
and interventional approaches for its management.
Just as pain itself received inadequate attention
from cancer clinicians in the past, other symp-
toms than pain are often under-assessed and un-
der-treated. Other symptoms, like cancer related
fatigue, sedation and cognitive dysfunction, have
only within recent years received attention by cli-
nicians and researchers. Research in epidemiolo-
gy, mechanisms and interventions is still in its in-
fancy and for that reason the interventions are
still not specified.
Psychostimulants offer new possibilities in man-
aging symptoms related to cancer and its treatment.
Out of the three classical psychostimulants (am-
phetamine, MP and pemoline) MP has been most
thoroughly evaluated in cancer patients. Because
amphetamine is feared for its abuse potential and
pemoline production has been stopped, MP remains
the classical and gold-standard psychostimulant,
which seems to have a future in palliative and sup-
portive treatment of cancer patients.
MP may potentially be effective in reducing seda-
tion, when used as adjuvant to strong opioids. How-
ever, the three randomised studies [2325] in this area
do not convincingly specify, that it is opioid induced
sedation and not sedation of other aetiologies, which
is antagonised. Furthermore, the findings need to be
confirmed by larger randomised, controlled studies.
MP has also been proposed as an antidepressant
in cancer patients, however, until now this has only
been studied in open non-randomised trials. As the
indications for fast acting antidepressants are obvi-
ous in cancer patients with short life expectancy
randomised trials are hardly needed.
The use of MP seems also to improve cognition
in cancer patients. However, due to the fact, that
randomised, controlled studies mostly were carried
out in children with leukaemia or brain tumours,
more evidence from patients with other malignan-
cies are needed.
A number of open-label studies have indicated a
possible usefulness of MP for the treatment of can-
cer-related fatigue. However, randomised, controlled
studies have not unambiguously confirmed that
methylphenidate is effective against cancer-related
fatigue [40, 41]. Discrepancy in results from the two
studies in treatment of fatigue may be related to
differences in study design, however, most likely the
doses of MP may have caused different outcomes.
In the first study a maximum of 20 mg of racemic
MP was used daily [41], whereas the other study the
average dose of d-MP in the study was 27.7 mg,
which is comparable to a dose of approximately
55 mg of the racemic mixture. Significant relief of
fatigue and improved memory was observed in
d-MP group compared with placebo [42]. Thus, high-
er doses of MP may be needed to improve cancer-
related fatigue. More evidence from dose-respond
trials could help to resolve this issue.
Modafinil, the novel vigilance and wake-promot-
ing agent, may be potentially effective in some symp-
toms that accompany cancer and its treatment. This
may include cancer-related fatigue, cognitive dys-
function and opioid induced sedation. Results from
studies investigating the efficacy of modafinil in fa-
tigue originating from multiple sclerosis and HIV
disease have encouraged for further studies in can-
cer patients. Current data are limited, but results of
currently ongoing studies are awaited. The lower
abuse potential and more specific effects seem to
be the main advantage of modafinil, when compar-
ing it to classical psychostimulants.
Conclusion
Opioid induced sedation, depression, cognitive dys-
function and fatigue are very frequent and severe symp-
toms in patients with cancer. The psychostimulants
are becoming increasingly important as pharmaco-
logical options in the treatment of these symptoms,
however, both classification and understanding of the
patophysiological mechanisms of the symptoms as
well as the specificity of available psychostimulants
make targeted treatments difficult. MP is still the gold-
en standard within the psychostimulants in palliative
medicine due to the level of evidence and a modest
side effect profile. However, new and exciting psycho-
stimulants may be awaited in the near future.
Advances in Palliative Medicine 2007, vol. 6, no. 1
www.advpm.eu30
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